HAL (France)
open access
Complete PET/CT extinction and subsequent risk of aortic dilation in patients with giant cell arteritis-related large vessel vasculitis treated with tocilizumab
Background The proportion of patients with giant cell arteritis (GCA)-related large vessel vasculitis (LVV) treated with tocilizumab (TCZ) who achieve a complete metabolic response on repeated 18 F-fluorodeoxyglucose positron emission tomography ( 18 FDG-PET)-CT (PET/CT) is unknown. Methods We condu
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- TocilizuMab discontinuAtion in GIant Cell Arteritis#883768
- TocILizumab in aorTitis in GCA (TILT)#852426
- Large Vessel Vasculitis: Recent Advances in Pathophysiology and Targeted Therapies#190610
- Giant Cell Arteritis and Differential Diagnoses Associated With Positive Temporal Artery Biopsy#911177
- Contribución del uso de sustancia de contraste endovenoso en PET/CT oncológico#626692
Record · ID 922931
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive